By Manas Mishra and Michael Erman
(Reuters) - Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.
That timeline makes it unlikely, however, that a vaccine will be available before the U.
S. election, as President Donald Trump has promised. Pfizer, which is developing the vaccine with German partner BioNTech <22UAy.F>, said that it may confirm if the vaccine.